The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
BUSINESS
Daiichi Sankyo Assigns COO Okuzawa as CEO from April
Daiichi Sankyo is promoting President and COO Hiroyuki Okuzawa to president and CEO effective as of April, the company said on January 31. Sunao Manabe, who currently serves as chairman and CEO, will be stepping down from the CEO role…
To read the full story
Related Article
- Daiichi Sankyo to Promote COO Okuzawa to CEO
January 31, 2025
BUSINESS
- Kyowa Kirin’s New Skipper Sees Further Growth Overseas, Vows to Cherish People
May 1, 2025
- Kyowa Kirin CEO Will Now Focus on Strategic Matters and External Dialogue
May 1, 2025
- Japan Pharma Sales Creep Up to 10.8 Trillion in FY2024: Encise
May 1, 2025
- Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer
May 1, 2025
- Moderna Taps Asia Chief as Japan Representative Director, Marketing Head as GM
April 28, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…